CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (11,675)	$ (22,521)	$ (73,186)	$ (60,516)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			740	455
Non-cash lease cost			446	611
Impairment of assets			635	0
Share-based compensation	2,106	2,330	6,626	6,502
Unrealized foreign currency transaction (gain) loss			8	17
Accretion of discount on marketable securities			13	197
Change in fair value of derivative liability			(776)	0	$ (200)
Non-cash interest expense associated with the sale of future royalties			2,605	0
Loss on extinguishment of liability related to the sale of future royalties	0	0	3,581	0
Changes in operating assets and liabilities:
Other receivables			1,366	3,088
Prepaid expenses and other current assets			7,133	2,758
Tax incentive receivables			312	797
Other assets			(2)	7
Accounts payable			1,483	2,007
Accrued expenses and other current liabilities			(6,257)	(3,185)
Deferred revenue, current and non-current			3,525	10,898
Other long-term liabilities			(31)	(29)
Operating lease liability			(434)	(605)
Net cash used in operating activities			(52,213)	(36,998)
Cash flows from investing activities:
Purchases of marketable securities			(26,970)	(13,601)
Proceeds from maturities of marketable securities			60,777	44,548
Net cash provided by (used in) investing activities			33,807	30,947
Cash flows from financing activities:
Repayment of liability related to the sale of future royalties			(54,485)	0
Proceeds from the issuance of common stock, net of issuance costs			10,334	5,357
Payment of offering and financing costs			0	(411)
Proceeds from stock option exercises			419	1,218
Net cash provided by financing activities			(43,732)	33,701
Net increase (decrease) in cash and cash equivalents			(62,138)	27,650
Cash, cash equivalents and restricted cash at beginning of period			112,584	85,209	85,209
Cash, cash equivalents and restricted cash at end of period	$ 50,446	$ 112,859	50,446	112,859	$ 112,584
Supplemental disclosure of non-cash activities:
Offering and financing costs in accounts payable and accruals			0	2,300
Pfizer Purchase Agreement [Member]
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs			$ 0	$ 27,537